Olanzapine systematic review

Based on a systematic review [68], olanzapine was superior to placebo in 6-week treatment studies of schizophrenia, although the attrition rates in the placebo-controlled studies were very high (olanzapine -61%, placebo -73%). The NNT was 8 (Cl 5-340). 

A systematic review of quetiapine included 12 studies [69]. The attrition rate in the four placebo-controlled studies was almost as high as in the olanzapine studies (quetiapine -53%, placebo -60%), the RR being 0.84 (Cl 0.7-0.9 NNT 11 Cl 7-55) thus, it is rather difficult to interpret the data with such Cl-values. [RR = relative risk in randomized controlled trials, the ratio of rate of negative events in the exposed group to the rate in controls.]... 

Duggan L, Fenton M, Rathbone J, Dardennes R, El-DosokyA, Indran S. Olanzapine for schizophrenia. [Systematic Review] The Cochrane Database of Systematic Reviews, 2, 2005. 

Systematic reviews Amisulpride and other atypical antipsychotic drugs (olanzapine, risperidone, and ziprasidone) have been compared in people with schizophrenia and schizophrenia-like psychoses in an analysis of 10 short- to medium-term trials with 1549 participants [56 ]. The overall attrition rate was considerable (35%), with no significant difference between the groups. Amisulpride was as effective as olanzapine and risperidone and more effective than ziprasidone. Amisulpride caused less weight gain than risperidone and olanzapine. Olanzapine was associated with a greater rise in blood glucose. There were no differences in cardiac and extrapyrami-dal reactions. 

Systematic reviews Ziprasidone has been compared with other atypical antipsychotic drugs in a systematic review [151 ]. The rate of premature study discontinuation was very high (59% n=3361). Ziprasidone was less efficacious than amisulpride, olanzapine, and risperidone, but based on limited data there were no significant differences in tolerability between ziprasidone and amisulpride or clozapine. Ziprasidone produced less weight gain than olanzapine (median difference, -3.8 95% Cl = -4.7, -3.0 ... 

Systematic reviews First-generation and second-generation antipsychotic drugs in patients with schizophrenia have been compared in a meta-analysis [14= ] (for an in-depth review, see SEDA-27, 50). The study included 150 double-blind, mostly shortterm, randomized clinical trials with 21 533 participants. Four second-generation antipsychotic drugs (amisulpride, clozapine, olanzapine, and risperidone) were better than first-generation ones for overall... 

A systematic review and meta-analysis of second-generation antipsychotics (SGAs) in the treatment of bipolar depression found considerable clinical and statistical heterogeneity of the data with a preponderance of quetiapine studies (9) compared to olanzapine (1) and aripiprazole (2) [22 ]. Adverse events were defined differently and... 

---